Cargando…

Mouse models of multiple myeloma: technologic platforms and perspectives

Murine models of human multiple myeloma (MM) are key tools for the study of disease biology as well as for investigation and selection of novel candidate therapeutics for clinical translation. In the last years, a variety of pre-clinical models have been generated to recapitulate a wide spectrum of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Marco, Botta, Cirino, Arbitrio, Mariamena, Grembiale, Rosa Daniela, Tagliaferri, Pierosandro, Tassone, Pierfrancesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929451/ https://www.ncbi.nlm.nih.gov/pubmed/29732008 http://dx.doi.org/10.18632/oncotarget.24614

Ejemplares similares

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
por: Di Martino, Maria T, et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
por: Amodio, Nicola, et al.
Publicado: (2019)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018)

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
por: Scionti, Francesca, et al.
Publicado: (2023)

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
por: Grillone, Katia, et al.
Publicado: (2022)

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
por: Caracciolo, Daniele, et al.
Publicado: (2022)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma
por: Juli, Giada, et al.
Publicado: (2019)

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
por: Raimondi, Lavinia, et al.
Publicado: (2016)

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
por: Tassone, P, et al.
Publicado: (2012)

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling
por: Russo, Mario, et al.
Publicado: (2020)

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
por: Zarone, Mayra Rachele, et al.
Publicado: (2017)

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
por: Scognamiglio, Immacolata, et al.
Publicado: (2014)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3fv0se6dqopb7bt8r3ck3p58pm